Printer Friendly

Medtronic Announces First Worldwide Implants of New Adapta Pacemaker; Device is One of Three New Physiologic, Fully Automatic Pacemakers Designed to Safeguard Cardiac Function.

MINNEAPOLIS -- Medtronic, Inc., (NYSE:MDT) today announced the start of a clinical study to evaluate the Medtronic Adapta(TM) pacemaker, which promotes natural heart activity for patients with a slow heart rhythm. Within the next year, Medtronic expects to introduce a portfolio of fully automatic pacemakers, the Adapta, Versa(TM), and Sensia(TM), in countries worldwide. These pacing systems are designed to provide physiologic pacing adapted to the needs of individual patients.

The first Adapta pacemaker implants were conducted by Associate Professor Goran Milasinovic, M.D., Ph.D., Clinical Center of Serbia, Belgrade; Johannes Sperzel, M.D., Kerckhoff-Klinik in Bad Nauheim, Germany; and Professor Karlheinz Tscheliessnigg, M.D., at Universitatsklinikum Graz, in Graz, Austria. The clinical study is a prospective, non-randomized, multicenter trial, involving up to 120 patients at 10 sites, to evaluate the safety and clinical performance of the Adapta pacing system.

The Adapta pacemaker offers the Medtronic-exclusive pacing mode called MVP(TM) or Managed Ventricular Pacing, which enables the device to be programmed to deliver pacing pulses to the heart's lower right chamber (ventricle) only when necessary, often less than 2 percent of the time. Other dual-chamber pacemakers often pace the right ventricle 90 percent or more of the time. Recent clinical studies have suggested that reducing this pacing stimulation may reduce the patient's risk of developing heart failure and atrial fibrillation, a potentially life-threatening irregular heartbeat.

"By reducing unwarranted ventricular pacing, we hope to reduce incidences of heart failure hospitalization," said Associate Professor Milasinovic, coordinating clinical investigator of the evaluation. "The Adapta's therapeutic features may enable physicians to better manage the co-morbidities that typically befall bradycardia patients."

The new pacemaker systems also incorporate an array of automatic features designed to help physicians improve pacing therapy and streamline the patient follow-up process, potentially minimizing the amount of time spent in a physician's office.

"We continue to aggressively research, develop and test new algorithms and therapy delivery techniques," said Steve Mahle, president, Medtronic Cardiac Rhythm Management. "We have applied physiologic pacing features to each of the products in the Adapta portfolio to potentially prevent disease progression."

Caution: The Adapta pacemaker is an investigational device. The device is limited by federal (or United States) law to investigational use only. Not available for sale in the United States.

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology, alleviating pain, restoring health, and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's Annual Report on Form 10-K for the year ended April 30, 2004. Actual results may differ materially from anticipated results.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jun 21, 2005
Words:443
Previous Article:Goldtech Completes Phase One Drilling and All Holes Hit Mineralization on Spanish Site.
Next Article:Caremark Rx, Inc. Announces Management Changes.
Topics:


Related Articles
Eleventh Circuit bars preemption in medical device case.
MINIMED GETS MAJOR MONEY; WORLD'S BIGGEST PACEMAKER COMPANY TO PAY $30 MILLION FOR MINORITY STAKE.
Beat generation: genetically modified stem cells repair heart.
Medtronic Announces FDA Approval of EnRhythm Pacemaker; Dual-Chamber Pacemaker Significantly Reduces Unnecessary Pacing in the Right Ventricle.
Medtronic Introduces Industry's First Catheter-Delivered Pacing Lead to Help Facilitate Selective Site Placement in the Right Heart Chambers.
The Larry King Cardiac Foundation Recipient of Medtronic Pacemakers, ICDs and Heart Valves; Donation Provides Cardiac Devices for Life-Saving...
Medicare Approves National Payment Policy Decision for Remote Monitoring of Implantable Cardiac Devices.
Medtronic Announces Market Introduction and FDA Approval of Three New Pacemakers; Physiologic, Fully Automatic Adapta Pacemaker Portfolio Safeguards...
Medtronic Simplifies Clinic Information Connectivity Challenge.
Medtronic Begins First-Ever Study to Evaluate New Pacemaker System Designed for Safe Use with MRI Machines.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters